top of page
Modern Office View

Strategic Scientific Advisory & Fractional Leadership

 

Translational strategy for biotech, investors, and innovation teams building human-relevant evidence.

 

NAMina Bio offers founder-led scientific advisory services for early-stage biotech companies, investors, technology developers, and translational research teams seeking rigorous evaluation of preclinical strategy, advanced model systems, and data-driven development plans.

 

Our advisory work is designed to help organizations assess scientific risk, strengthen translational positioning, and build more credible paths from discovery-stage biology to decision-ready evidence.

Bridging Scientific Depth and Strategic Execution

 

The gap between promising early-stage discovery and clinically relevant evidence is one of the most critical risk points in biotechnology.

 

Evaluating a new asset, platform, or translational workflow requires more than a conventional review of a pitch deck or publication package. It requires an understanding of disease biology, preclinical model limitations, human-relevant systems, data quality, regulatory direction, and commercial readiness.

 

Led by Dr. Paola Dama, PhD, Founder & CEO of NAMina Bio, this advisory service brings together over 15 years of international experience in molecular oncology, immunotherapy, gene therapy, 3D tumor models, organoids, New Approach Methodologies, and biotech business development.

Founder-Led Expertise

 

Dr. Paola Dama brings a rare combination of academic, industry, and entrepreneurial experience across oncology, gene therapy, immunotherapy, and advanced preclinical modeling.

 

Selected credentials include:

 

  • Founder & CEO, NAMina Bio Corp

  • BioLabs@NYU Langone resident startup footprint, New York

  • Former Senior Scientific Product & Business Development Manager, VectorBuilder

  • Visiting Research Fellow, University of Sussex

  • Editorial Board Member, Cancer Gene Therapy

  • Reviewer for leading oncology and translational journals

  • Recipient of Cancer Gene Therapy Reader’s Choice recognition in 2022 and 2024

  • Experience across pharma-sponsored immuno-oncology research, CRISPR functional genomics, viral vectors, 3D tumor biology, and translational oncology

 

 

Engagement Formats

 

Advisory engagements can be structured based on the level of support required.

 

Examples include:

 

  • One-hour strategic consultation

  • Scientific due-diligence review

  • Investor or partner-readiness audit

  • Fractional scientific leadership

  • White paper or technical narrative development

  • Custom advisory mandate for biotech, pharma, or investment teams

 

All engagements are scoped individually based on objectives, timeline, confidentiality requirements, and deliverables.

​
 

​

NAMs, Organoid & Preclinical Strategy

Accelerate your transition to human-relevant preclinical systems.

1 hLocation 1

Service Description

Strategic advisory support for organizations transitioning to human-relevant, mechanism-driven preclinical systems. Services include integrating NAMs into discovery programs, evaluating 3D models and organoids, and ensuring alignment with emerging regulatory expectations. Services may include: Strategy for integrating New Approach Methodologies into discovery or validation programs Evaluation of 3D models, organoids, microphysiological systems, and co-culture workflows Guidance on assay robustness, biological relevance, and data interpretation Alignment with emerging regulatory and translational expectations around non-animal methods Scientific white papers, technical briefs, and strategic communication materials

Contact Details

  • 500 Terry Francine Street, 6th Floor, San Francisco, CA 94158

    123-456-7890

    info@mysite.com

bottom of page